Edition:
India

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

2.64USD
17 Nov 2017
Change (% chg)

$-0.03 (-0.94%)
Prev Close
$2.66
Open
$2.67
Day's High
$2.74
Day's Low
$2.62
Volume
1,181
Avg. Vol
5,722
52-wk High
$5.35
52-wk Low
$2.62

Chart for

About

TapImmune Inc. is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers.... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): --
Shares Outstanding(Mil.): 10.16
Dividend: --
Yield (%): --

Financials

BRIEF-Tapimmune Q3 loss earnings per share $0.39‍​

* Tapimmune provides third quarter 2017 corporate and clinical update

16 Nov 2017

CARE ratings for Indian debt instruments-Oct 20

Oct 20 Below are the ratings awarded by Credit Analysis and Research Ltd. (CARE) for local debt instruments as of October 18, 2017. COMPANY INSTRUMENT RATING AMOUNT MOVEMENT (RS.MLN) ------- ---------- ------ ------- --------- SHORT TERM RATINGS: ------------------- Arvind Pd Composites Pvt Ltd ST Bk Fac

20 Oct 2017

BRIEF-TapImmune appoints Peter Hoang as president and CEO

* TapImmune appoints Peter Hoang as president and chief executive officer

25 Sep 2017

BRIEF-Tapimmune files for‍​ resale of 4.4 mln shares of common stock held by selling stockholders

* Tapimmune Inc - Files for‍​ resale 4.4 million shares of common stock which are currently held by selling stockholders - SEC filing Source text: [http://bit.ly/2hjwILz] Further company coverage:

21 Sep 2017

BRIEF-TapImmune reaches 50 pct patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

* TapImmune reaches 50% patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

27 Jun 2017

BRIEF-TapImmune to raise $6.82 million in a private placement

* Tapimmune inc. Enters into definitive agreements to raise $6.82 million in a private placement from accredited investors and from the exercise of warrants by existing institutional investors

22 Jun 2017

Earnings vs. Estimates

No consensus analysis data available.